Loading...
Market
Evotec Stock Price Exceeds €11 per Share by End of 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from exchanges where Evotec is listed, such as Xetra
Story
Halozyme Proposes €2 Billion Takeover of Evotec at €11 Per Share, 27% Premium
Nov 14, 2024, 09:30 PM
Halozyme Therapeutics is reportedly exploring a takeover of the German drugmaker Evotec, with a proposed acquisition valued at approximately €2 billion ($2.1 billion). The offer includes a cash payment of €11 per share, representing a 27% premium over Evotec's last closing price. This potential acquisition aims to enhance Halozyme's drug discovery and development portfolio. The interest from Halozyme comes as Evotec has garnered attention in the biotechnology sector, with various reports confirming the ongoing discussions between the two companies.
View original story
Similar markets
Increase by 0-5% • 25%
Increase by 5-10% • 25%
Increase by 10-15% • 25%
Increase by more than 15% • 25%
Outperforms DAX by more than 10% • 25%
Outperforms DAX by up to 10% • 25%
Performs similar to DAX • 25%
Underperforms DAX • 25%
Takeover completed • 25%
Takeover offer made but not completed • 25%
No takeover offer made • 25%
Triton sells its stake • 25%
Decrease by more than 20% • 25%
Decrease by less than 20% • 25%
Increase by less than 20% • 25%
Increase by more than 20% • 25%
Below $100 • 25%
$100 - $150 • 25%
$150 - $200 • 25%
Above $200 • 25%
